Instructions for Participation
In order to complete this CME activity and receive CME credit, please follow the instructions below.
It should take approximately 1.0 hour to successfully complete this activity. This activity must be completed during the period from August 1, 2007, through August 1, 2008.
- Listen to the Targeting A2A Receptors in Parkinson’s Disease webcast.
- Complete the post-test and evaluation found within the activity, and submit to the International Secretariat.
Following your completion of the evaluation and achieving at least 70% on the post test, an MDS CME Certificate will be generated for immediate printing.
If you are unable to view the evaluation and post test, please click here to print a PDF version. Please fax the completed evaluation and post test to:
Catherine Breckenridge, Program Manager, 414-276-3349 (fax)
The relevant certificate will be sent to you in the mail within 3-4 weeks.
Targeting A2A Receptors in Parkinson’s Disease
Supported through an educational grant from Kyowa Pharmaceutical Inc.
The content of this Enduring Educational Activity was derived from presentations at The Movement Disorder Society’s 10th International Congress of Parkinson’s Disease and Movement Disorders.
Activity Overview
The progress that has been made in understanding the role of non-dopaminergic receptors in the pathophysiology of Parkinson’s disease (PD) has provided impetus for the development of non-dopaminergic therapies in the management of this debilitating disease. A promising therapy which has been developed for PD is the adenosine2A receptor antagonist, Istradefyline. This CME Enduring Activity will review the role of adenosine system in the pathophysiology of PD and the results of clinical trials on Istradefyline, and will enable participants to understand the potential and role of this new class of drugs for PD.
Accreditation Statement
The Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Movement Disorder Society designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Target Audience
This activity has been designed to meet the educational needs of Movement Disorder specialists, general neurologists, physicians-in-training, and other healthcare professionals interested in the current research and approaches for the diagnosis and treatment of Parkinson’s disease.
Learning Objectives
At the conclusion of the activity, participants should be able to:
- Describe the role of adenosine system in the basal ganglia in relation to Parkinson’s disease;
- Define the potential role of adenosine antagonists in the management of Parkinson’s disease;
- Discuss the current evidence for the use of adenosine antagonists in Parkinson’s disease.
Chairs
Andrew H.V. Schapira, DSc, MD
London, United Kingdom
Louis CS Tan, FRCP
Singapore, Singapore
Faculty
Peter Jenner, BPharm, PhD, DSc
London, United Kingdom
Peter A. LeWitt, MD
Southfield, Michigan, USA